CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $2,477,971 | -26.9% | 54,786 | -34.3% | 0.22% | -20.3% |
Q4 2022 | $3,390,779 | -12.3% | 83,414 | +41.0% | 0.27% | -17.4% |
Q3 2022 | $3,867,000 | +0.1% | 59,175 | -6.9% | 0.33% | +0.3% |
Q2 2022 | $3,863,000 | -67.7% | 63,569 | -66.7% | 0.33% | -65.2% |
Q1 2022 | $11,969,000 | -11.1% | 190,685 | +7.3% | 0.94% | +9.2% |
Q4 2021 | $13,471,000 | – | 177,769 | – | 0.86% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |